Post COVID and Apheresis – Where are we Standing?

Author:

Steenblock Charlotte1ORCID,Walther Romy1,Tselmin Sergey1,Jarzebska Natalia12,Voit-Bak Karin3,Toepfner Nicole4,Siepmann Timo5,Passauer Jens1,Hugo Christian1,Wintermann Gloria6,Julius Ulrich1,Barbir Mahmoud7,Khan Tina Z.7,Puhan Milo A.8,Straube Richard1,Hohenstein Bernd1,Bornstein Stefan R.19,Rodionov Roman N.12

Affiliation:

1. Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

2. University Center for Vascular Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

3. Zentrum für Apherese- und Hämofiltration am INUS Tagesklinikum, Cham, Germany

4. Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

5. Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

6. Department of Psychotherapy and Psychosomatic Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

7. Department of Cardiology, Harefield Hospital, Harefield, United Kingdom of Great Britain and Northern Ireland

8. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

9. School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom of Great Britain and Northern Ireland

Abstract

AbstractA continual increase in cases of Long/Post COVID constitutes a medical and socioeconomic challenge to health systems around the globe. While the true extent of this problem cannot yet be fully evaluated, recent data suggest that up to 20% of people with confirmed SARS-CoV-2 suffer from clinically relevant symptoms of Long/Post COVID several weeks to months after the acute phase. The clinical presentation is highly variable with the main symptoms being chronic fatigue, dyspnea, and cognitive symptoms. Extracorporeal apheresis has been suggested to alleviate symptoms of Post/COVID. Thus, numerous patients are currently treated with apheresis. However, at present there is no data from randomized controlled trials available to confirm the efficacy. Therefore, physicians rely on the experience of practitioners and centers performing this treatment. Here, we summarize clinical experience on extracorporeal apheresis in patients with Post/COVID from centers across Germany.

Funder

Deutsche Forschungsgemeinschaft

Publisher

Georg Thieme Verlag KG

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,General Medicine,Endocrinology, Diabetes and Metabolism

Reference65 articles.

1. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study;L Huang;Lancet Respir Med,2022

2. Long-COVID, metabolic and endocrine disease;S R Bornstein;Horm Metab Res,2022

3. Unexplained post-acute infection syndromes;J Choutka;Nat Med,2022

4. Blood viscosity of COVID-19 patient: a preliminary report;B Joob;Am J Blood Res,2021

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3